Last Updated: November 16, 2026

Details for Patent: 10,471,087

« Back to Dashboard


Which drugs does patent 10,471,087 protect, and when does it expire?

Patent 10,471,087 protects KYGEVVI and is included in one NDA.

This patent has sixty patent family members in twenty-seven countries.

Summary for Patent: 10,471,087
Title:Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
Abstract:The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
Inventor(s):Michio Hirano, Caterina Garone, Ramon Marti
Assignee: Columbia University in the City of New York
Application Number:US15/736,092
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 10,471,087

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc KYGEVVI doxecitine; doxribtimine FOR SOLUTION;ORAL 219792-001 Nov 3, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,471,087

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3310362 ⤷  Start Trial C20265012 Finland ⤷  Start Trial
European Patent Office 3310362 ⤷  Start Trial 301385 Netherlands ⤷  Start Trial
European Patent Office 3310362 ⤷  Start Trial CR 2026 00027 Denmark ⤷  Start Trial
European Patent Office 3310362 ⤷  Start Trial LUC50054 Luxembourg ⤷  Start Trial
European Patent Office 3310362 ⤷  Start Trial PA2026522 Lithuania ⤷  Start Trial
European Patent Office 3310362 ⤷  Start Trial 2026C/722 Belgium ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.